Lucid Diagnostics Inc. — Director's Dealing 2025

May 23, 2025

SEC Form 4/A — Form 4/A

Issuer: Lucid Diagnostics Inc. (LUCD)
CIK: 0001799011
Period of Report: 2025-05-20

Reporting Person: Matheis Dennis (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-05-20	Common Stock	P	187098	$1.2950	Acquired	402541	Direct
2025-05-21	Common Stock	P	129684	$1.3226	Acquired	532225	Direct
2025-05-22	Common Stock	P	33218	$1.3184	Acquired	565443	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $1.265 to $1.30. inclusive. The reporting person undertakes to provide to Lucid Diagnostics Inc., any security holder of Lucid Diagnostics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form4.

F2: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $1.315 to $1.32, inclusive.

F3: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $1.305 to $1.32, inclusive.

F4: Includes 52,718 shares of Lucid common stock distributed on a pro rata basis to the reporting person by a limited partnership of which the reporting person is a limited partner.